| Metric | Value (₹ Cr) | Q1 FY27 | Q2 FY26 |
|---|---|---|---|
| Revenue | 2.6K | 6.9% | 43.3% |
| Total Income | 2.7K | 5.9% | 38.2% |
| Expenditure | 2.1K | 8.8% | 41.3% |
| PBT | 601.12 | 3.0% | 28.6% |
| Net Profit | 462.39 | 2.0% | 30.8% |
| OPM | 27.96% | 1.05pp | 2.57pp |
| NPM | 17.41% | 1.41pp | 0.99pp |
| EPS | 10.24 | 2.0% | 29.8% |
Strong Order Book, Stalling Profit Momentum
Revenue surged 43% YoY and PAT grew 31%, but the quarter reveals a profit crisis hiding in the headline: QoQ PAT fell 2% despite 7% revenue growth, capex guidance was slashed 53%, and margins are compressing under commodity pressure. The long-term growth story remains intact; near-term execution is deteriorating.
₹2,632 Cr
+43.3%
+6.9%
Sequential slowdown
₹462 Cr
+30.8%
-2.0%
Profit declined
The year-on-year numbers invite celebration — revenue up 43%, PAT up 31%, order book raised to ₹16,260 Cr from ₹15,000 Cr. But flip to the quarter-on-quarter picture and the story inverts. Revenue grew 6.9% sequentially, yet net profit fell 2%. That gap — strong topline growth with stalling profit — is the quarter's central tension.
Where the profit drain is coming from
Operating margin compressed to 28.0% from the prior year's 29.0% — a 100 bps headwind against the 29-30% guidance band. The solar segment EBITDA margin of 29.3% came in line with guidance, but transformer margin collapsed from 22% in Q1 to 12% in Q2 as commodity inflation (steel, copper, aluminum) hit BOM costs. Management expects normalization to 15%, but near-term margin recovery is uncertain. More troubling: despite bringing 5.6 GW of new module capacity and 7 GW of cell capacity into the system, the company is not achieving operating leverage. Revenue scaling faster than profit suggests mix dilution (higher-volume, lower-margin modules consuming cells; inventory buildup of ₹1.5% of sales adding working capital drag). The cell line ramp is ramping — but not yet monetizing.
Q2 revenue ₹2,656 Cr, up 38.2% YoY
₹2,632 Cr, up 43.3% YoY
Overstated (mgmt revenue figure cited 1% high; actual YoY outpaced guidance)
PAT ₹462 Cr, up 30.8% YoY
₹462.4 Cr, up 30.8% YoY
Supported exactly
Solar EBITDA margin 29.3%, PAT margin 17.9%
Company OPM 28.0%, NPM 17.4%; segment-level margin slightly higher
Supported
Order book ₹16,260 Cr, up from ₹15,000 Cr prior
Confirmed; ₹1,260 Cr (+8.4%) net increase
Supported
7 GW TOPCon cell line 70% utilization by March FY27
Cell line commissioned, trial runs underway, commercial production starting Nov 2026
Supported (on track for 70% target)
QoQ PAT stable / modest growth
QoQ PAT -2.0%
Contradicted (sequential profit declined)
What shifted on this call — three critical moves
1. Order book raised. Premier upgraded order book from ₹15,000 Cr to ₹16,260 Cr (+₹1,260 Cr), driven by ₹4,001 Cr in new cell and module wins in Q2 alone. This is substantive. The company is winning market share despite DCR module pricing collapsing to ₹21-22 per watt in a commoditized market. Long-term visibility improves. 2. Capex guidance slashed 53%. FY27 capex revised from ₹5,100 Cr to ₹2,400 Cr. This is the quarter's most alarming signal. Management attributed the cut to bulk of cell and module capacity already live, with "marginal leftovers" remaining — but cutting capex by ₹2,700 Cr contradicts the urgency of the 10 GW ingot-wafer roadmap (Phase 1: 5 GW by Dec 2027, Phase 2: +5 GW by June 2028) that was just announced. Either capital is tighter than the bullish narrative suggests, or the capex plan itself has been downgraded. Either interpretation signals caution. 3. Transformer margin under pressure; ingot-wafer announced. Transformer EBITDA margin fell from 22% in Q1 to 12% in Q2 due to commodity cost inflation. Management guided normalization to 15% — implying Q2 was an anomaly, not a trend. But 10 percentage points of margin swing in one quarter raises questions about cost control. In parallel, the ingot-wafer plan was unveiled: 10 GW capacity by June 2028. This is a growth lever, but it requires capex — which just got cut. The mismatch is stark.
Order book ₹16,260 Cr; Q2 wins ₹4,001 Cr (robust demand)
7 GW cell line on track; commercial production Nov 2026
10 GW ingot-wafer capacity plan (5 GW Dec 2027, +5 GW June 2028)
Transformer 4 GVA commissioned; trebling target over 3 years
BESS operationalization Q2 FY28; government policy support likely
QoQ PAT -2.0% despite 6.9% revenue growth
Capex guidance cut ₹2,700 Cr (53% reduction from ₹5,100 Cr)
OPM 28.0% vs. 29-30% guidance; 100 bps compression YoY
Transformer margin Q2 12% vs. Q1 22% (commodity inflation)
Inventory buildup ₹1.5% of sales; working capital drag
DCR module pricing ₹21-22/watt in competitive market
China ALMM equipment export policy decision due Nov 15
Capex guidance cut 53% (₹5,100 → ₹2,400 Cr)
HighSignals capital constraint or reprioritization away from original growth plan. Contradicts 10 GW ingot-wafer ambition and near-term BESS capex needs. If capex stays cut, growth velocity decelerates; if reinstated, it pressures near-term earnings and cash.
Margin compression from commodity inflation
HighOPM 28% vs. 29-30% guidance; transformer margin fell 22% → 12% Q1-Q2. New capacity is not generating operating leverage. Module BOM inflation (aluminum, copper, silicon, silver) ongoing; pricing power limited in commodity DCR segment.
QoQ profit decline despite revenue growth
HighPAT -2% QoQ vs. +6.9% revenue signals deleverage. Operating costs scaling with volume. Mix shift (higher-volume modules consuming cells; lower-margin business) not offset by cell line operating leverage. Profit momentum broken.
China ALMM export policy (Nov 15 decision)
MediumEquipment export restrictions could delay or constrain ingot-wafer capex sourcing. Phase 1 (5 GW by Dec 2027) may slip. Impacts long-term ingot-wafer roadmap and capex timing. If ingot-wafer is deprioritized due to China policy, the growth narrative weakens further.
DCR module pricing deflation
MediumDCR modules at ₹21-22/watt in highly competitive market; non-DCR pricing even lower. Pricing power limited. Near-term margin recovery depends on cost reduction, not price realization. Risk of competitive pricing collapse in next 2-3 years as Chinese capacity oversupply persists.
Inventory and working capital pressure
Medium₹1.5% of sales inventory buildup due to cell line ramp and shipping delays. Temporary but reduces cash conversion and liquidity. If new capex is constrained and inventory doesn't convert to sales quickly, FCF pressure emerges.
How the street is positioned
The stock has repriced hard: ₹884 on Nov 11 is 36% below its all-time high of ₹1,388. It trades below its 20-day, 50-day, and 200-day moving averages — a bearish technical setup. RSI of 47.6 is neutral, not oversold, suggesting downside risk persists if fundamentals don't stabilize. Ownership reveals institutional conviction diverging from insider views. FII ownership rose 2.2pp QoQ to 7.92%, and DII rose 4.27pp to 17.97% — institutions are accumulating on weakness. But promoter ownership fell 5.37pp to 58.81%, revealing the founding family trimming. In May 2026, promoter-linked entities Jasveen Kaur Saluja and Charandeep Singh Saluja sold ~32.5 lakh shares at ₹955 per share — near the quarter's highs — while Edelweiss MF, Nomura, Tata MF, and HDFC MF bought aggressively. This divergence is a red flag: insiders distributed into strength; institutions accumulated into weakness. The capex cut and margin compression may have prompted the insider exit. The market is pricing near-term caution. The 36% drawdown from ATH, technical positioning below all key averages, and insider selling despite strong order book suggest the street has lost confidence in near-term execution.
1 · China ALMM policy (Nov 15)
Government decision on ultra-thin wafer equipment exports will determine ingot-wafer capex feasibility and Phase 1 timeline (5 GW by Dec 2027). A ban or hard restriction forces Plan B (Taiwan sourcing, SE Asia alternatives) and delays capex. Clarity by Nov 15 is binary: green light or amber.
2 · Cell line ramp and operating leverage (Dec 2026–Mar 2027)
7 GW cell line to move from trial to 25-30% CUF in Dec and target 70% by March FY27. This is the profit inflection catalyst. If ramp hits target and cell margin realization improves from ₹0.12-0.14/watt to ₹0.16+, sequential profit will reaccelerate in Q3-Q4. If ramp stalls or margin remains under pressure, the profit decline is not temporary.
3 · Q3–Q4 margin recovery (commodities reset)
Transformer margin must normalize from 12% toward 15% as commodity cycle eases. Solar segment margin must hold 29-30%. If both stabilize and OPM recovers to 29%+, the capex cut becomes a near-term de-risking. If margins remain compressed or decline further, the capex cut signal a loss of pricing power or structural margin pressure.
4 · BESS operationalization and regulatory clarity (Q2 FY28 and beyond)
Battery Energy Storage launch in Q2 FY28 is critical for next-phase growth. Government KUSUM 2.0, Surya Ghar 2.0, and BESS subsidy/localization framework announcements pending. Early BESS profitability and order book will signal viability. If BESS ramps and government support materializes, a new growth vector emerges; if regulatory framework is unclear or demand softer than expected, BESS becomes a capex sink rather than a growth driver.
Premier Energies delivered the headline wins — revenue +43%, PAT +31%, order book +8% to ₹16,260 Cr. But the quarter is not a step-change in the story. QoQ profit fell 2% despite revenue growth, margins compressed under commodity pressure, and management slashed capex by 53%. The 7 GW cell line and 10 GW ingot-wafer roadmap remain compelling long-term; near-term execution risk is mounting.
The verdict: Hold. Premier is not broken — order book, capacity additions, and transformer/BESS diversification are real. But the capex cut signals caution on growth ambition, and profit momentum has stalled. Watch three things: (1) cell line ramp to 70% by March FY27 and margin realization; (2) transformer margin recovery to 15%+ as commodities reset; (3) China ALMM policy decision (Nov 15) on ingot-wafer sourcing. If cell ramp hits, margins stabilize, and capex is reinstated or BESS demand surprises on the upside, the -36% repricing may overshoot. If margins remain compressed, capex stays cut, or China policy restricts equipment, downside extends. Track organic EBITDA and operating margin as the lead indicators. Until margins recapture 29% and cell line hits 50%+ utilization, the stock likely trades in a hold range.
Q2 FY27 Earnings: Order Momentum & BESS Expansion in Focus
The solar cell and module manufacturer reports with ₹4,001 Cr in fresh orders in hand, a newly operational 10.6 GW cell facility, and dual battery storage JVs ramping. Street expects revenue in line with the 50%-plus FY27 growth arc, but the real watch is operational execution and margin defence as capex cycles peak.
The Setup: Scale Without Surrender on Margins
Premier Energies enters Q2 FY27 with a ₹4,001 Cr order book achievement announced Oct 9—solar modules (2,308 MW) and EPC project execution, the core cash-generation levers. The firm reported Q1 FY27 with revenue surging 34.1% YoY to ₹25,076 Mn and PAT rising 53.3% YoY. Street consensus expects FY27 total revenue to rise 50%-plus on the 10.6 GW newly operational solar cell facility (India's largest, commissioned Sep 21) and pent-up solar-plus-storage demand. The crux: can Q2 sustain Q1's momentum while the company absorbs capex on its 12 GWh battery storage joint ventures (RCT India, RCT Nexor Energy) ramping toward first-phase commercial ops by June 2027?
~₹21,000 Cr
Anchored to Q1 run-rate (₹25,076 Mn) and FY27 50% growth arc
29–30%
FY27 guidance; Q1 EBITDA margin was 29.0% (down 110 bps YoY due to mix shift toward lower-margin modules)
~₹15,000 Cr
Reported post-FY26 close; Q2 inflows of ₹4,001 Cr refresh the pipeline
Peak cycle
7 GW cell + 6 GWh BESS phase-1 + 3 GW inverter build-out; free cash flow pressure expected through FY27–28
What Defines a Strong vs. Weak Print
A strong Q2 would show revenue in line with or ahead of the ₹19,500–22,000 Cr range (extrapolating Q1 plus summer order seasonality), EBITDA margins holding above 28%, order inflows materially ahead of ₹4,000 Cr, and commentary signaling margin recovery as cell/module capacity utilization deepens. Early battery storage ramp commentary and supply-chain confirmations for the RCT India 12 GWh JV would add upside sentiment. A weak print would miss revenue expectations below ₹19,500 Cr, see margins compress below 28% (signaling pricing or mix pressure), reveal order momentum slowing below ₹3,500 Cr, or voice caution on BESS execution timelines. Any working-capital stress or capex overruns would trigger downgrades.
On Track for Full-Year Guidance?
Through Q1 FY27, Premier is tracking the 50% full-year growth target well (Q1 +34.1%, but from a lower base post-IPO capex). To reach the implied ₹12,500–13,500 Cr full-year revenue run, Q3–Q4 must average ₹23,000–24,000 Cr each, assuming Q2 lands near ₹21,000 Cr. The 10.6 GW solar cell facility (operational since Sep 21) supplies domestic + export modules, and the order backlog of ₹15,000 Cr provides line-of-sight revenue for ~12 months at current run-rate. Margin defence at 29–30% EBITDA depends on cell/module pricing holding steady (no major India/China import surge) and BESS capex not leaking into operational P&L yet. The real test: Q4 execution when both solar and BESS ramps are in full swing.
What the Street Says
Since Last Quarter: The Filing Scan
1 · 7 GW TOPCon Cell Facility Commissioned (Sep 21)
India's largest solar cell plant, raising total capacity to 10.6 GW. Operational ramp-up should show in Q2 volumes and cost-per-unit metrics. Watch for pricing traction in H2 as supply ramps.
2 · ₹4,001 Cr Order Inflows in Q2 (Oct 9 announcement)
2,308 MW solar modules + EPC project execution. This is the lifeblood of near-term revenue; sustained order momentum above ₹3,500 Cr/quarter is the Street's bar for a 50% FY27 outcome.
3 · 12 GWh BESS JV Term Sheet Signed (Sep 10, Oct 15)
Binding agreements with RCT India and RCT Nexor Energy. First 6 GWh targeted for June 2027; full 12 GWh by FY28. No P&L contribution expected Q2/Q3, but strategic value and regulatory de-risking evident. Watch for capex burn on the Telangana site.
4 · Singapore Subsidiary Incorporation (Sep 23)
PE Horizon Pte. Ltd. for clean energy trading/consulting. Routine structural move; low near-term impact on Q2 consolidated results.
5 · Promoter & Insider Share Moves (May 25, 2026)
Block deals at ₹955 saw promoter selling (Jasveen/Charandeep Saluja) offset by MF/insurance buying (Nomura, SBI Life, HDFC MF, Tata MF, Kotak Life). Net: FII +220 bps, DII +427 bps QoQ to Sep 2026. No insider warnings; rotation is normal. Promoter stake down to 58.81% from 64.18% in Q1, within acceptable range for a growing large-cap.
What to Watch on Result Day (Nov 4)
1 · Revenue & Margin Mix
Is Q2 revenue ₹19,500–22,000 Cr? Are EBITDA margins holding 28%+, or is pricing pressure (China imports, oversupply) biting? A margin miss below 28% would trigger downgrades; a hold or beat at 29%+ validates the capacity-leverage thesis.
2 · Order Inflows Trajectory
Are Q2 fresh orders ₹4,000+ Cr? Is the order backlog growing or static? If guidance says FY27 full-year target is ₹4,000 Cr + inflows every quarter, miss that and the market reprices lower.
3 · BESS JV Execution & Capex Outlook
How much capex was deployed in Q2 on the Telangana 6 GWh facility? Does management reaffirm June 2027 Phase-1 commissioning? Cost overruns or timeline slips would weaken sentiment. Also, first commercial BESS order wins (beyond the JV commitment) would be a green flag for demand.
Premier Energies is in the thick of a scale-up: a newly operational 10.6 GW solar cell facility, ₹4,001 Cr in fresh Q2 orders, and twin BESS JVs (12 GWh total) climbing toward first-phase revenue contributions by mid-2027. Q2 earnings are the first real-time check on whether the order pipeline is translating into cash and whether capacity ramp is accretive to margins or a drag. Street is moderately bullish (median target ₹1,135, current ₹845.2) but execution-conscious—margin compression or order softness would trigger quick repricing. FII/DII accumulation (net +640 bps QoQ) suggests smart money is long on the growth arc, but the stock's 39% discount to ATH leaves room for disappointment. Watch revenue momentum, margin defence, and BESS timeline credibility.
Order book strong, capex cut signals caution amid margin pressure
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade B
Order book raised (₹16,260 Cr vs ₹15,000 Cr), cell ramp on track, margins within range. Capex guidance cut 53% from ₹5,100 Cr to ₹2,400 Cr.
Optimistic
next 1–2 quarters
Very Optimistic
multi-year
Strong order book ₹16,260 Cr and cell ramp support medium-term growth, but delivered Q2 shows margin compression (OPM 28% vs 29-30% guidance), QoQ PAT decline -2%, and capex cut signals capital constraints. China policy uncertainty and battery profitability unproven.
₹2631.9 Cr
Revenue · +43.3% YoY₹462.4 Cr
Reported PAT · +30.8% YoYCompressing
Margins · vs guidance: MixedDid the claims hold up?
Q2 revenue ₹2,656 Cr, up 38.2% YoY
OVERSTATEDDelivered ₹2,631.9 Cr, up 43.3% YoY; mgmt claim lower than actual YoY but revenue figure 1% high
PAT ₹462 Cr, up 30.8% YoY
METDelivered ₹462.4 Cr, up 30.8% YoY
Solar EBITDA margin 29.3%, PAT margin 17.9%
METDelivered OPM 28.0%, NPM 17.4%; slightly higher than full-co EBITDA/PAT margins
Order book ₹16,260 Cr, up from ₹15,000 Cr prior
METOrders mentioned; prior guidance was ₹15,000 Cr, so ₹16,260 Cr is raise
7 GW cell line commissioned, 70% utilization by March FY27
METCell line commissioned, trial runs underway, commercial production starting Nov 2026; ramp tracking guidance
QoQ PAT stable/modest growth
MISSDelivered QoQ PAT -2.0%; quarter was flat to slightly down QoQ
Earnings quality
What changed since the last call
Order book up
Upgrade₹16,260 Cr vs ₹15,000 Cr prior call; ₹4,001 Cr new cell/module wins in highly competitive market
Capex cut
DowngradeFY27 revised to ₹2,400 Cr from ₹5,100 Cr plan; bulk of cell/module expansion complete, now marginal leftovers
Transformer margin
DowngradeQ1 margin 22%, Q2 margin 12%; commodity cost increases (steel, copper) impacted, expect normalize to 15% going forward
Ingot-wafer
New10 GW capacity planned by June 2028 (Phase 1: 5 GW by Dec 2027, Phase 2: +5 GW by June 2028); wafer supplier TBD pending China policy
The Q&A
Analysts pressed hard on China policy, margin trends, inventory buildup, and capex priorities. Management acknowledged China uncertainty (policy due Nov 15) but maintained confidence in BOM strategy. Defended inventory as ramp-related, not inventory error. Deferred capex details and forward growth plans pending semiconductor/BESS clarity.
Battery manufacturing localization — Shubham Borade, ICICI Securities
AnsweredBESS operationalization expected Q2 2027. Localizing container manufacturing and fire suppression systems in-house. 7 GW cell line MNRE approval expected by Nov; inspection underway from NISE for ALMM enrolment.
DCR pricing and order mix — Apoorva Bahadar, IIFL Capital
AnsweredDCR pricing INR21-INR22 per watt on average; C&I INR21.5; IPP INR20.5; non-DCR INR12.75-INR13; inventory buildup due to ramp-up and delivery delays, expect normalization by March.
China ALMM policy risk — Sumit Kishore, Axis Capital
PartialChina policy not yet clear; awaiting final announcement Nov 15. Already imported high-tech equipment for Naidupeta cell line, which gives competitive advantage. Most equipment suppliers have SE Asia backup. Hoping for resolution.
Transformer capacity ramp and margins — Kunal Shah, DAM Capital
AnsweredCell line 25-30% CUF in Dec, ramp to 70% by end-March. Transformer 4 GVA already commissioned. Expect 80-90% ramp over 3 years. Normalized transformer margin 15%; Q2 was 12% due to commodity cost increases.
Non-DCR order book and SECI tender — Bharani, Avendus Spark
PartialNo product-by-product breakdown given. SECI tender treated as IPP at ~INR17-18/watt introductory rate to build credentials; not indicative of market pricing. Cells/modules DCR 48%, modules non-DCR 20%, rest DCR business.
U.S. expansion and China policy — Sahil Sheth, Anand Rathi
PartialU.S. and Europe are geographies of interest. Make in America policy is positive. Cell manufacturing in U.S. being finalized with JV partner; 12-18 months timeline. No firm commitment yet.
BESS demand and China component sourcing — Amit, UBS
AnsweredBESS demand currently 50-60 GW annually. Expecting strong growth. 40% localization achievable with cell-to-pack, pack-to-container, and software in-house. No ban on BESS manufacturing components from China.
Order book mix and capex outlook — Amit Bhinde, Axis Capital
AnsweredRetail ~35-40%, C&I and utilities rest. Non-DCR ~25-30% of order book. FY27 capex ~₹2,400 Cr; next two quarters ~₹700 Cr each. Capex for cell/module expansion largely complete.
International geography expansion — Bharani, Avendus Spark (second question)
DodgedU.S. and Europe remain geographies of interest for policy push. Strong policy support for domestic manufacturing. Evaluating opportunities in both markets and internationally.
Cell order book decline explanation — Sahil Sheth, Anand Rathi (second question)
AnsweredCell order book declined as 5.6 GW module line commissioned; we are consuming more cells internally. Prefer to use cells for module consumption, gradually reducing cell sales.
Guidance
FY27 revenue growth mid-to-high 30s% expected (implied from order book execution)
MediumOrder book ₹16,260 Cr supports growth. Cell ramp execution key. Macro headwinds (commodity inflation, shipping) risk.
Solar segment EBITDA margin 29-30%, PAT margin 17.9-18.5% sustainable
MediumQ2 delivered 29.3% EBITDA, 17.9% PAT. Commodity price volatility and DCR mix pressure offset by cell line operating leverage.
Transformer margin normalize to 15% from 12% Q2 (commodity reset assumption)
MediumQ1 was 22%, Q2 12% due to steel/copper increases. Management expects stabilization as commodity cycle eases.
FY27 capex ~₹2,400 Cr (revised down from ₹5,100 Cr announced)
HighBulk of cell/module expansion complete. Next 2 quarters ~₹700 Cr each. Battery/ingot-wafer projects being evaluated for future capex.
Risks the call surfaced
Commodity price volatility
HighTransformer margin fell from 22% (Q1) to 12% (Q2); commodity cost headwinds ongoing. Module BOM inflation impacting realizations.
China export control policy
HighChina government finalizing ALMM (ultra-thin wafer) export policy by Nov 15. Impact on ingot-wafer equipment import timelines and 10 GW capex schedule.
Margin compression from pricing
MediumDCR module pricing range INR21-INR22/watt with aggressive competition. Non-DCR pricing declining. Margin sustainability at risk.
Battery Energy Storage regulatory risk
MediumBESS profitability dependent on government KUSUM 2.0, Surya Ghar 2.0, and BESS scheme announcements. Operating margins TBD. 40% localization requirement achievable but capex-intensive.
Inventory and working capital pressure
MediumInventory buildup ~₹1.5% of sales. Management attributes to ramp-up preparation and shipping congestion. Temporary, expect normalization by Q4.
Management
Score 6/10. Chiranjeev Saluja (MD) confident on strategy but cautious on near-term macro; Vinay Rustagi detailed on pricing, transparent on inventory challenges; deflected on product-by-product margins and forward capex details. Delivered on cell line commissioning (7 GW), transformer capacity (4 GVA), order book ramp (₹16,260 Cr). Capex guidance cut 53% signals slower execution pace. QoQ PAT -2% indicates execution challenges despite strong YoY.
1 · Nov 15, 2026
China policy on ALMM equipment exports; clarity on ingot-wafer sourcing
2 · Dec 2026
7 GW cell line commercial production ramp; 25-30% CUF expected
3 · Mar 2027
Cell line 70% utilization; ingot-wafer plant Phase 1 commissioning Dec 2027
China policy uncertainty and battery profitability unproven.